Likes Subject
Started the day up... whats going on Robinsold 6 minutes ago
Ouch...down -18.89% do far today. Fmello 9 minutes ago
Nice movement this week, hope it's due to leakage... bubbarayjr 02/04/23 6:07 AM
We're up +$1.18 (77.63%) in the past 5 Fmello 02/03/23 4:40 PM
Stock manipulation. midastouch017 02/03/23 12:24 AM
Up 46.58% over the past 5 days. Fmello 02/02/23 7:18 PM
Biotech Showcase Fmello 01/30/23 11:13 AM
Brainstorm Cell Therapeutics (BCLI) Receives a Buy from Fmello 01/11/23 5:13 PM
BrainStorm Preps for Type A NurOwn Meeting, Shakes Fmello 01/07/23 11:07 AM Fmello 01/01/23 10:55 PM
That's definitely good news. Hopefully they can set Fmello 12/27/22 9:16 AM
BrainStorm Cell Therapeutics Announces Type A Meeting with midastouch017 12/27/22 8:27 AM
BrainStorm Cell Therapeutics Submits Type A Meeting Request Fmello 12/12/22 10:32 AM
West Virginia man battling ALS hoping FDA reverses Fmello 12/07/22 11:15 AM Fmello 12/06/22 12:33 PM
No annual shareholder meeting date has been released condoe3 12/05/22 5:35 PM
Fmello 12/03/22 1:55 AM
Dramatic letter from Esteban Bulrich to Joe Biden Fmello 11/30/22 2:26 PM Fmello 11/29/22 1:34 PM
Fort Smith man losing hope after FDA denies Fmello 11/25/22 1:37 PM
I Am ALS and Veterans with ALS send Fmello 11/23/22 3:53 PM
Stevens Nation Responds to FDA's Refusal to File
Fmello 11/22/22 8:41 PM
Any idea what caused this huge spike to
Fmello 11/22/22 1:38 PM
BrainStorm Vows to Push for Adcomm Meeting on Fmello 11/14/22 1:20 PM
Mike Hensen & Michelle Lorenz going LIVE @ Fmello 11/10/22 5:51 PM Fmello 11/10/22 12:43 PM
BCLI - The End Of Story! midastouch017 11/10/22 8:37 AM
BrainStorm Cell Therapeutics Receives Refusal to File Letter Fmello 11/10/22 8:34 AM
NurOwn Continues to Show Benefit in Rapidly Advancing ALS Fmello 11/09/22 7:23 PM
NurOwn Stromal Cell Therapy Continues to Show Positive Fmello 11/09/22 7:19 PM
BrainStorm Cell Therapeutics to Announce Third Quarter Results midastouch017 11/08/22 12:35 AM Fmello 11/07/22 7:42 AM
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's midastouch017 11/07/22 7:33 AM
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Fmello 11/07/22 7:27 AM
“Every day thousands of patients die from aging-associated sokol 10/29/22 9:46 AM
BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive midastouch017 10/20/22 6:09 AM Fmello 10/13/22 3:16 PM
This is from a post on the No Fmello 10/12/22 7:25 PM
Hopefully the latter, but my guess is the murocman 10/12/22 6:22 PM
At 26:07, Lindborg mentions, Fmello 10/12/22 2:43 PM Fmello 10/12/22 2:04 PM
Phase III trial of NurOwn shows evidence of bubbarayjr 10/10/22 8:59 PM
Hard to imagine BCLI not being a slam bubbarayjr 10/08/22 5:59 PM
BrainStorm Presents New Biomarker Analyses from NurOwn's Phase midastouch017 10/07/22 12:08 PM
More and more analyst are predicting approval. bubbarayjr 10/04/22 8:52 PM
Conclusion When viewed as a whole, we believe the midastouch017 10/04/22 11:21 AM
BCLI: Relvyrio™ Approval Shows FDA Flexibility for ALS Treatments… midastouch017 10/04/22 11:20 AM
FDA's approval of AMLX's drug is very positive bubbarayjr 10/02/22 8:44 AM
Seeking Alpha: Excellent Summary on BCLI bubbarayjr 10/02/22 8:37 AM
Not weird at all. Just as expected midastouch017 09/30/22 2:03 PM
Likes Subject

6 minutes ago
9 minutes ago
02/03/23 4:40 PM
02/03/23 12:24 AM
02/02/23 7:18 PM
01/30/23 11:13 AM
11/23/22 3:53 PM
11/22/22 1:38 PM
11/10/22 12:43 PM
11/10/22 8:37 AM
11/07/22 7:42 AM
10/12/22 7:25 PM
10/12/22 6:22 PM
10/12/22 2:43 PM
10/10/22 8:59 PM
10/08/22 5:59 PM
10/04/22 11:21 AM
10/02/22 8:37 AM
09/30/22 2:03 PM

BrainStorm Cell Therapeutics Inc. (BCLI)

Posts (Today)
Posts (Total)

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. 

Brainstorm Cell Therapeutics Inc.

1325 Avenue of Americas
28th Floor
New York, NY 10019
United States


Most Liked Posts
(Last 30 Days)
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
BCLI Latest News
Most Liked Posts
(Last 30 Days)
New Post